{"disease":{"id":"ras-wild-type","name":"ras wild type"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1201577","indication_name":"K-Ras wild-type, EGFR-expressing mCRC with FOLFIRI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201577","indication_name":"K-Ras wild-type, EGFR-expressing mCRC with irinotecan","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201577","indication_name":"K-Ras wild-type, EGFR-expressing mCRC as single-agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CETUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":20,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03263663","title":"Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"PD Dr. med. Volker Heinemann","has_results":false},{"nct_id":"NCT03043950","title":"Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)","phase":"","overall_status":"COMPLETED","enrollment_count":647,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT02792478","title":"Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study","phase":"","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04561336","title":"Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false},{"nct_id":"NCT02292758","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT07490119","title":"Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04080843","title":"Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03263429","title":"Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":true},{"nct_id":"NCT03983993","title":"Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT03275974","title":"Glutamine PET Imaging Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03300609","title":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"University of Southern California","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}